Armen Shanafelt - Dec 9, 2021 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role: Director
Signature: /s/ Steven Weber, by power of attorney
Stock symbol: AGLE
Transactions as of: Dec 9, 2021
Transactions value $: $549,692
Form type: 4
Date filed: 12/13/2021, 07:41 PM
Previous filing: Jun 9, 2021
Next filing: Jun 9, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGLE	Common Stock	Purchase	$447K	+122K		$3.67^*	122K	Dec 9, 2021	Direct	F1
transaction	AGLE	Common Stock	Purchase	$49.3K	+13.5K	+11.1%	$3.65^*	135K	Dec 10, 2021	Direct
transaction	AGLE	Common Stock	Purchase	$53.6K	+14.7K	+10.85%	$3.65^*	150K	Dec 13, 2021	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.53 to $3.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Content

The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.53 to $3.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares purchased at each separate price within the range set forth herein.